Stopping a GLP-1: the weight-regain data and what actually helps

What happens when people stop

Three trials stopped a GLP-1 drug on purpose and measured what followed. They give a consistent answer.

STEP 1 treated adults with obesity with semaglutide 2.4 mg High, the Wegovy dose, or placebo for 68 weeks, alongside a lifestyle program, and then stopped everything. In the 327 people followed for another year, those on semaglutide had lost 17.3% of their weight at week 68 and regained 11.6 percentage points of it by week 120, leaving a net loss of 5.6%. That is about two-thirds of the loss regained in a year, and most of the improvements in heart and metabolic risk factors went back toward baseline as well ¹.

STEP 4 asked the question directly. All 803 participants first took semaglutide for 20 weeks and lost 10.6% on average; they were then randomized to keep taking it or to switch to placebo for 48 weeks. Those who continued lost a further 7.9%, while those switched to placebo regained 6.9%, a difference of 14.8 percentage points. Gastrointestinal side effects were reported by 49.1% of those who continued against 26.1% on placebo ².

SURMOUNT-4 did the same with tirzepatide High. After 36 weeks at the highest tolerated dose, the 670 participants had lost 20.9%. Over the next 52 weeks, those who continued lost another 5.5%, while those switched to placebo regained 14.0% of their weight. At week 88, 89.5% of the continuing group had kept at least 80% of their earlier loss, against 16.6% of the placebo group; from the start of the trial, the total loss was 25.3% against 9.9% ³.

A 2026 systematic review in the BMJ pooled 37 studies and 9,341 people who stopped weight-loss medicines. Weight came back at an average of 0.4 kg a month, faster than after behavioural weight-loss programmes, by 0.3 kg a month, whatever the size of the initial loss, and the authors projected every cardiometabolic marker back at baseline within 1.4 years ⁴.

The health gains go with the weight

A post hoc analysis of SURMOUNT-4 looked at the 308 people switched to placebo who had lost at least 10% on tirzepatide, and grouped them by how much they regained. Most regained at least a quarter of their loss within a year: 54 regained less than 25%, 77 regained 25% to 50%, 103 regained 50% to 75% and 74 regained 75% or more. The more they regained, the more their health markers reversed. Waist size grew by 0.8 cm in the group that regained least and by 14.7 cm in the group that regained most, and systolic blood pressure rose by 6.8 to 10.4 mm Hg across the groups. In those who regained less than a quarter, waist size, non-HDL cholesterol and fasting insulin were not significantly different from when tirzepatide stopped ⁵.

Why the weight comes back

A July 2026 review of the mechanisms describes the regain as front-loaded: much of it happens in the first months after stopping. It points to several processes acting at once: appetite returning as the drug's signal disappears, a compensatory rise in hunger hormones such as ghrelin, and shifts in the balance of incretin hormones. The authors are careful to say that direct evidence for some of these, including changes in GLP-1 receptor signalling during long treatment, is still limited ⁶.

What actually helps

Staying on treatment

The clearest evidence is the simplest. In STEP 4 and SURMOUNT-4, the people who kept taking the drug kept losing weight, and those who stopped regained ^{2 3}. The STEP 1 authors concluded that obesity behaves as a chronic disease and that ongoing treatment is needed to keep the improvements ¹.

Exercise during treatment

The one randomized trial that followed people for a year after stopping comes from Copenhagen. Adults with obesity first lost 13.1 kg on an eight-week low-calorie diet, then spent a year on supervised exercise, liraglutide 3.0 mg High daily, both, or placebo. One year after all treatment ended, people who had had both weighed 5.1 kg less than those who had had liraglutide alone, measured from the end of the diet. They were also more likely to have kept off at least 10% of their starting weight: 7.2 times the odds of the placebo group and 4.2 times the odds of the liraglutide-only group. In the year after stopping, the liraglutide-only group regained 6.0 kg more than the exercise-only group, whose weight and body composition held ⁷.

Tapering and reduced-frequency dosing

The evidence here is thin. A retrospective case series of 30 adults who had reached a weight plateau on weekly semaglutide or tirzepatide moved them to dosing usually every other week at the same dose; over an average of 36.3 weeks, their weight went from 74.1 kg to 72.4 kg, and fat continued to fall while muscle mass held ⁸. A case series has no comparison group, so it cannot show the change caused the result. The July 2026 review notes some randomized evidence that lower-intensity maintenance may slow regain compared with stopping abruptly, but says whether structured tapering can help people come off the drug altogether is unknown and needs prospective trials ⁶.

If you are planning to stop

Expect most of the lost weight to return within a year unless something else replaces the drug's effect, and expect the first months to matter most ^{1 6}. The best-tested addition is a structured exercise programme started while still on treatment ⁷. Any change of dose or schedule, including spacing injections out, is a decision to make with the prescriber; as of October 2, 2026, no tapering schedule has been shown in a prospective trial to make stopping work.

Frequently asked questions

Will I regain weight after stopping semaglutide or Wegovy?

Most people do. One year after stopping semaglutide 2.4 mg in the STEP 1 extension, participants had regained 11.6 of the 17.3 percentage points they had lost, about two-thirds, leaving a net loss of 5.6%.

How fast does weight come back after stopping a GLP-1?

A 2026 meta-analysis of 37 studies found an average regain of 0.4 kg a month after weight-loss medicines stopped, faster than after behavioural programmes. A 2026 review describes the regain as concentrated in the first months.

Does tapering off a GLP-1 prevent weight regain?

It has not been tested properly. A case series of 30 patients who switched to every-other-week dosing kept their weight, but had no comparison group, and a July 2026 review says structured tapering still needs prospective trials.

What helps keep weight off after stopping a GLP-1?

Supervised exercise during treatment has the best evidence: in a Copenhagen trial, people who combined it with liraglutide were 5.1 kg lighter a year after stopping than those who took liraglutide alone. Staying on treatment keeps the loss in every withdrawal trial.

Related on Grey Peptides

• Semaglutide
• Tirzepatide
• Muscle loss on GLP-1s

Sources

1. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab, 24(8), 1553-1564. PMID: 35441470 · doi:10.1111/dom.14725
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414-1425. PMID: 33755728 · doi:10.1001/jama.2021.3224
3. Aronne, L. J., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38-48. PMID: 38078870 · doi:10.1001/jama.2023.24945
4. West, S., et al. (2026). Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, 392, e085304. PMID: 41500720 · doi:10.1136/bmj-2025-085304
5. Horn, D. B., et al. (2026). Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med, 186(2), 157-167. PMID: 41284285 · doi:10.1001/jamainternmed.2025.6112
6. Damhof, M. A., et al. (2026). Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies. Diabetes Obes Metab, 28(10), 8769-8776. PMID: 42396734 · doi:10.1111/dom.71075
7. Jensen, S. B. K., et al. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine, 69, 102475. PMID: 38544798 · doi:10.1016/j.eclinm.2024.102475
8. Wong, M., et al. (2026). Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity (Silver Spring), 34 Suppl 1(Suppl 1), 112-120. PMID: 41732031 · doi:10.1002/oby.70137

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.